BioCentury | Jul 17, 2014
Strategy

Partnering in pediatrics

...the commercial transition of selected projects. In February, Alexion gained an exclusive option to acquire Prothelia Inc....
...directly from the University of Nevada, Reno . PRT-01 is laminin-111 protein replacement therapy that Prothelia...
...Cincinnati, Ohio Moderna Therapeutics Inc. , Cambridge, Mass. Persepsys Biomedical LLC , Cincinnati, Ohio Prothelia Inc....
BioCentury | Feb 17, 2014
Company News

Alexion, Prothelia, University of Nevada deal

...Alexion gained an exclusive option to acquire rare disease company Prothelia, which is developing preclinical protein...
...dystrophy type 1A (MDC1A). Alexion may exercise its option upon achievement of undisclosed R&D milestones. Prothelia...
...treat MDC1A and Duchenne muscular dystrophy (DMD). Life Sciences Advisory and Foley Hoag advised Prothelia. Prothelia...
BioCentury | Feb 17, 2014
Finance

Highlights of weekly biotech stock moves

...10%) to $180.55 last week after gaining an exclusive option to acquire rare disease company Prothelia Inc....
BioCentury | Feb 14, 2014
Company News

Alexion gains option to acquire Prothelia

...Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) gained an exclusive option to acquire rare disease company Prothelia Inc. (Milford, Mass...
...developing preclinical protein replacement therapy PRT-01 to treat merosin-deficient congenital muscular dystrophy type 1A (MDC1A). Prothelia...
...muscular dystrophy caused by mutations in the gene that encodes laminin alpha-2 ( LAMA2 ). Prothelia...
Items per page:
1 - 4 of 4
BioCentury | Jul 17, 2014
Strategy

Partnering in pediatrics

...the commercial transition of selected projects. In February, Alexion gained an exclusive option to acquire Prothelia Inc....
...directly from the University of Nevada, Reno . PRT-01 is laminin-111 protein replacement therapy that Prothelia...
...Cincinnati, Ohio Moderna Therapeutics Inc. , Cambridge, Mass. Persepsys Biomedical LLC , Cincinnati, Ohio Prothelia Inc....
BioCentury | Feb 17, 2014
Company News

Alexion, Prothelia, University of Nevada deal

...Alexion gained an exclusive option to acquire rare disease company Prothelia, which is developing preclinical protein...
...dystrophy type 1A (MDC1A). Alexion may exercise its option upon achievement of undisclosed R&D milestones. Prothelia...
...treat MDC1A and Duchenne muscular dystrophy (DMD). Life Sciences Advisory and Foley Hoag advised Prothelia. Prothelia...
BioCentury | Feb 17, 2014
Finance

Highlights of weekly biotech stock moves

...10%) to $180.55 last week after gaining an exclusive option to acquire rare disease company Prothelia Inc....
BioCentury | Feb 14, 2014
Company News

Alexion gains option to acquire Prothelia

...Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) gained an exclusive option to acquire rare disease company Prothelia Inc. (Milford, Mass...
...developing preclinical protein replacement therapy PRT-01 to treat merosin-deficient congenital muscular dystrophy type 1A (MDC1A). Prothelia...
...muscular dystrophy caused by mutations in the gene that encodes laminin alpha-2 ( LAMA2 ). Prothelia...
Items per page:
1 - 4 of 4